

CUMULATIVE 12 MONTH ROLLING ANTIBIOGRAM (NON-URINES) / JUN 2021 46867240 KINDRED HOSPITAL SEATTLE-FIRST

	ANTII	VIICRO)BIAL	SUSC	EPTIE	BILITIE	S - F	ERCENT SUSCEPTIE			
	EC	ENTBSP	ENTS	ENTS ENTFA	KLEBSP	PROTSP	PSEUAE	SERRSP	STAPA	STAPA MRSA	STAPA MSSA
# ISOLATES	29*	26*	27*	24*	59	23*	88	21*	68	21*	47
AMIKACIN							98				
AMOXICILLIN/CA	62	0			53	100		5			
AMPICILLIN	45				0	83					
CEFAZOLIN		0			0			0			
CEFEPIME	75	62		,	66	91	64	95			
CEFTAZIDIME							68				
CEFTRIAXONE	59				39	91		75			
CEFUROXIME	55	0			41	91		0			
CIPROFLOXACIN	79	96			71	87	83	100	66	10	91
CLINDAMYCIN									72	48	83
ERTAPENEM	93				97	100					
ERYTHROMYCIN									47	10	64
GENTAMICIN	86	96			95	100	84	95	97	95	98
IMIPENEM	90	85			76		74				
LEVOFLOXACIN	79	100			75	87	65	100	66	10	91
LINEZOLID									100	100	100
MEROPENEM	93	81			81	100	81	95			
MOXIFLOXACIN									91		91
NITROFURANTOIN					26						
OXACILLIN									69	0	100
PENICILLIN			93	100		-			0	. 0	0
PIPERACILLIN							75				
PIPERACILLIN/TAZOBACTAM	86				69	100					
QUINUPRISTIN/DALFOPRISTIN									100		100

N .			
EC	Escherichia coli	PSEUAE	Pseudomonas aeruginosa
ENTBSP	Enterobacter species	SERRSP	Serratia species
ENTS	Enterococcus species	STAPA	Staphylococcus aureus
ENTS ENTFA	Enterococcus faecalis	STAPA MRSA	Staphylococcus aureus /MRSA
KLEBSP	Klebsiella species	STAPA MSSA	Staphylococcus aureus /MSSA
DDOTED	Destaus appoins		

^{*}Percent (%) susceptible data are calculated only when 20 or more isolates of a given species have been tested. Greater statistical validity of %S is seen when 30 or more isolates are included. This Report is a summary of data collected by the Client and provided to the Laboratory and of certain Laboratory test results previously provided to the Client. It is the sole responsibility of the Client to determine that the Report is accurate, to determine what actions, if any, to take as a result of the Report, and to determine that the Report complies with any applicable laws, regulations, or guidelines. LABORATORY EXPRESSLY DISCLAIMS ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, AND LABORATORY EXPRESSLY EXCLUDES ANY LIABILITY FOR ANY LOSS OR DAMAGE, DIRECT OR CONSEQUENTIAL, INCURRED BY CLIENT OR OTHER PERSONS OR ENTITIES RESULTING FROM OR IN ANY WAY RELATED TO THIS REPORT.



CUMULATIVE 12 MONTH ROLLING ANTIBIOGRAM (NON-URINES) / JUN 2021 46867240 KINDRED HOSPITAL SEATTLE-FIRST

	ANTII	ANTIMICROBIAL			SUSCEPTIBILITIES - PERCENT SUS						SCEPTIBLE		
	EC	ENTBSP	ENTS	000000000000000000000000000000000000000	KLEBSP	PROTSP	PSEUAE	SERRSP	STAPA	decontract and a second			
				ENTFA						MRSA	MSSA		
# ISOLATES	29*	26*	27*	24*	59	23*	88	21*	68	21*	47		
RIFAMPIN									100	100	100		
TETRACYCLINE	83	77			71	0		43	94	86	98		
TICARCILLIN					-		64						
TOBRAMYCIN	90	96			85	100	97	95					
TRIMETH-SULFA	83	81			86	87		100	96	86	100		
VANCOMYCIN			100	100					100	100	100		
								-					

EC	Escherichia coli	PSEUAE	Pseudomonas aeruginosa
ENTBSP	Enterobacter species	SERRSP	Serratia species
ENTS	Enterococcus species	STAPA	Staphylococcus aureus
ENTS ENTFA	Enterococcus faecalis	STAPA MRSA	Staphylococcus aureus /MRSA
KLEBSP	Klebsiella species	STAPA MSSA	Staphylococcus aureus /MSSA
PROTSP	Proteus species		

^{*}Percent (%) susceptible data are calculated only when 20 or more isolates of a given species have been tested. Greater statistical validity of %S is seen when 30 or more isolates are included. This Report is a summary of data collected by the Client and provided to the Laboratory and of certain Laboratory test results previously provided to the Client. It is the sole responsibility of the Client to determine that the Report is accurate, to determine what actions, if any, to take as a result of the Report, and to determine that the Report complies with any applicable laws, regulations, or guidelines. LABORATORY EXPRESSLY DISCLAIMS ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, AND LABORATORY EXPRESSLY EXCLUDES ANY LIABILITY FOR ANY LOSS OR DAMAGE, DIRECT OR CONSEQUENTIAL, INCURRED BY CLIENT OR OTHER PERSONS OR ENTITIES RESULTING FROM OR IN ANY WAY RELATED TO THIS REPORT.



CUMULATIVE 12 MONTH ROLLING ANTIBIOGRAM (NON-URINES) / JUN 2021 46867240 KINDRED HOSPITAL SEATTLE-FIRST

	ANTIN	IICROBIAL	SUSCEF	TIBILITIE	NT SU	NT SUSCEPTIBLE				
	STEM									
# ISOLATES	27*									
CEFTAZIDIME	37		Commission of the Commission o				on the second) A	
CHLORAMPHENICOL	56									
EVOFLOXACIN	89									
TRIMETH-SULFA	93				·					
						_				
									1.	
	,				ļ					

STEM

Stenotrophomonas maltophilia

^{*}Percent (%) susceptible data are calculated only when 20 or more isolates of a given species have been tested. Greater statistical validity of %S is seen when 30 or more isolates are included. This Report is a summary of data collected by the Client and provided to the Laboratory and of certain Laboratory test results previously provided to the Client. It is the sole responsibility of the Client to determine that the Report is accurate, to determine what actions, if any, to take as a result of the Report, and to determine that the Report complies with any applicable laws, regulations, or guidelines. LABORATORY EXPRESSLY DISCLAIMS ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, AND LABORATORY EXPRESSLY EXCLUDES ANY LIABILITY FOR ANY LOSS OR DAMAGE, DIRECT OR CONSEQUENTIAL, INCURRED BY CLIENT OR OTHER PERSONS OR ENTITIES RESULTING FROM OR IN ANY WAY RELATED TO THIS REPORT.

			•
			•
•			
		•	
			•
			· .
		•	



CUMULATIVE 12-MONTH ROLLING ANTIBIOGRAM (URINES) / JUN 2021 46867240 KINDRED HOSPITAL SEATTLE-FIRST

	ANTII	VIICRO)BIAL	SUSC	EPTIE	ILITIE	S - F	ERCE	VT SL	JSCEP	TIBLE
	EC	ENTS	KLEBSP	PROTSP	PSEUAE						
# ISOLATES	37	24*	33	21*	41						
AMIKACIN					100						
AMOXICILLIN/CA	62		82								
AMPICILLIN	32		0	67							
CEFEPIME	81		84	95	73						
CEFTAZIDIME					73						
CEFTRIAXONE	73			95							
CEFUROXIME	51		64	76							
CIPROFLOXACIN	76	63	82	81	83						
ERTAPENEM	100		100	100							
GENTAMICIN	84		97	100	98						
IMIPENEM	100		100		73						
LEVOFLOXACIN	76	63	94	81	78						
MEROPENEM	100		100	100	78						
NITROFURANTOIN	97	79	30	5							
PENICILLIN		71									
PIPERACILLIN					85						
PIPERACILLIN/TAZOBACTAM	92		96	95							
TETRACYCLINE	76	25	61	10							
TICARCILLIN					70				·		
TOBRAMYCIN	81		85	95	100						
TRIMETH-SULFA	73		73	81							
VANCOMYCIN		79									

ORGANISM ACRONYM KEY

EC ENTS KLEBSP PROTSP Escherichia coli Enterococcus species Klebsiella species Proteus species

PSEUAE Proteus species
PSEUAE Pseudomonas aeruginosa

*Percent (%) susceptible data are calculated only when 20 or more isolates of a given species have been tested. Greater statistical validity of %S is seen when 30 or more isolates are included. This Report is a summary of data collected by the Client and provided to the Laboratory and of certain Laboratory test results previously provided to the Client. It is the sole responsibility of the Client to determine that the Report is accurate, to determine what actions, if any, to take as a result of the Report, and to determine that the Report complies with any applicable laws, regulations, or guidelines. LABORATORY EXPRESSLY DISCLAIMS ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, AND LABORATORY EXPRESSLY EXCLUDES ANY LIABILITY FOR ANY LOSS OR DAMAGE, DIRECT OR CONSEQUENTIAL, INCURRED BY CLIENT OR OTHER PERSONS OR ENTITIES RESULTING FROM OR IN ANY WAY RELATED TO THIS REPORT.





CUM 12 MONTH ROLLING ANTIBIOGRAM (UR & NON-UR) / JUN 2021 46867240 KINDRED HOSPITAL SEATTLE-FIRST

	ANTI	WICR(BIAL	SUSC	EPTIE	BILITIE	S - F	PERCENT SUSCEPTIBL				
	ACIS	ALCX	BURKSP	CHRBSP	CITRSP	DIPTHE	EC	EGGELE	ENTESP	ENTS	ENTS ENTFA	
# ISOLATES	9*	4*	6*	1*	11#	1*	59	1*	32	49	40	
AMOXICILLIN/CA							64	annes ann Frankrik af Frankrik af a Frankrik ar an A	0			
AMPICILLIN							41					
CEFAZOLIN						. : : . : . : . : :	4		0			
CEFEPIME							79		59			
CEFTRIAXONE							68					
CEFUROXIME							58		0			
CIPROFLOXACIN							80		97	63		
ERTAPENEM							96					
GENTAMICIN							86		97			
IMIPENEM							95		84			
LEVOFLOXACIN							80		100	63		
MEROPENEM							97		81			
NITROFURANTOIN							94		50	79		
PENICILLIN										82	98	
PIPERACILLIN/TAZOBACTAM							88					
TETRACYCLINE							80		72	25		
TOBRAMYCIN							86		97			
TRIMETH-SULFA							78		81			
VANCOMYCIN										90	100	

ACIS	Acinetobacter species	EC	Escherichia coli
ALCX	Achromobacter species	EGGELE	Eggerthella lenta
BURKSP	Burkholderia species	ENTBS₽	Enterobacter species
CHRBSP	Chryseobacterium gleum	ENTS	Enterococcus species
CITRSP	Citrobacter species	ENTS ENTFA	Enterococcus faecalis
DIDTHE	Dinhtheroids		

^{*}Percent (%) susceptible data are calculated only when 20 or more isolates of a given species have been tested. Greater statistical validity of %S is seen when 30 or more isolates are included. This Report is a summary of data collected by the Client and provided to the Laboratory and of certain Laboratory test results previously provided to the Client. It is the sole responsibility of the Client to determine that the Report is accurate, to determine what actions, if any, to take as a result of the Report, and to determine that the Report complies with any applicable laws, regulations, or guidelines. LABORATORY EXPRESSLY DISCLAIMS ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, AND LABORATORY EXPRESSLY EXCLUDES ANY LIABILITY FOR ANY LOSS OR DAMAGE, DIRECT OR CONSEQUENTIAL, INCURRED BY CLIENT OR OTHER PERSONS OR ENTITIES RESULTING FROM OR IN ANY WAY RELATED TO THIS REPORT.



CUM 12 MONTH ROLLING ANTIBIOGRAM (UR & NON-UR) / JUN 2021 46867240 KINDRED HOSPITAL SEATTLE-FIRST

	ITMA	MICRO)BIAL	SUSC	EPTIE	ILITIE	S - F	PERCE	NT SUSCEP		TIBLE
	ENTS ENTFM	KLEBSP	MORM	PROTSP	PROVSP	PSEUAE	PSEUSP	RAGUOR	SERRSP	STAPA	STAPA MRSA
	CNIFM										MINOA
# ISOLATES	4*	79	7*	34	3*	107	4*	1*	22*	68	21*
AMIKACIN						98	-				
AMOXICILLIN/CA		65		100					5		
AMPICILLIN		0		74							
CEFAZOLIN		0							0		
CEFEPIME		72		94		66			95		
CEFTAZIDIME						70					
CEFTRIAXONE		46		94					76		
CEFUROXIME		51		82					0		
CIPROFLOXACIN		76		82		83			100	66	10
CLINDAMYCIN										72	48
ERTAPENEM		98		100							
ERYTHROMYCIN										47	10
GENTAMICIN		96		100		87			95	97	95
IMIPENEM		82				77					
LEVOFLOXACIN		79		82		68			100	66	10
LINEZOLID										100	100
MERDPENEM		86		100		82			95		
MOXIFLOXACIN										91	
NITROFURANTOIN		29		3							
OXACILLIN										69	0
PENICILLIN										0	0
PIPERACILLIN						78					
PIPERACILLIN/TAZOBACTAM		80		97							
QUINUPRISTIN/DALFOPRISTIN										100	

		DOTUGD	D
ENTS ENTFM	Enterococcus faecium	PSEUSP	Pseudomonas sp.(non-aeruginosa)
KLEBSP	Klebsiella species	RAOUOR	Raoultella ornithinolytica
MORM	Morganella morganii	SERRSP	Serratia species
PROTSP	Proteus species	STAPA	Staphylococcus aureus
PROVSP	Providencia species	STAPA MRSA	Staphylococcus aureus /MRSA
PSEUAE	Pseudomonas aeruginosa		

^{*}Percent (%) susceptible data are calculated only when 20 or more isolates of a given species have been tested. Greater statistical validity of %S is seen when 30 or more isolates are included. This Report is a summary of data collected by the Client and provided to the Laboratory and of certain Laboratory test results previously provided to the Client. It is the sole responsibility of the Client to determine that the Report is accurate, to determine what actions, if any, to take as a result of the Report, and to determine that the Report complies with any applicable laws, regulations, or guidelines. LABORATORY EXPRESSLY DISCLAIMS ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, AND LABORATORY EXPRESSLY EXCLUDES ANY LIABILITY FOR ANY LOSS OR DAMAGE, DIRECT OR CONSEQUENTIAL, INCURRED BY CLIENT OR OTHER PERSONS OR ENTITIES RESULTING FROM OR IN ANY WAY RELATED TO THIS REPORT.



CUM 12 MONTH ROLLING ANTIBIOGRAM (UR & NON-UR) / JUN 2021 46867240 KINDRED HOSPITAL SEATTLE-FIRST

	ANTII	VICRO	BIAL	SUSC	EPTIE	BILITIE	S – F	- PERCENT SUSCEPTIBLE				
	ENTS ENTFM			eggggespoors and an authorist and a				RAOLIOR		99999940000044000440	00-900-00000-0000-0000-000	
# ISOLATES	4*	79	7*	34	3*	107	4*	1*	22*	68	21*	
RIFAMPIN								a para de la compansa de la compans	OOD TO SEE STATE OF THE PARTY O	100	100	
TETRACYCLINE		71		3					41	94	86	
TICARCILLIN						64						
TOBRAMYCIN		87		97		97			91			
TRIMETH-SULFA		82		82					100	96	86	
VANCOMYCIN										100	100	
		FIII. = II										
									··· · · · · · · · · · · · · · · · · ·			
					<u>-</u>							
		V									******************	

ENTS ENTFM	Enterococcus faecium	PSEUSP	Pseudomonas sp.(non-aeruginosa)						
KLEBSP	Klebsiella species	RAOUOR	Raoultella ornithinolytica						
MORM	Morganella morganii	SERRSP	Serratia species						
PROTSP	Proteus species	STAPA	Staphylococcus aureus						
PROVSP	Providencia species	STAPA MRSA	Staphylococcus aureus /MRSA						
PSFIIAE	Depudomonae apruginosa	•	- 1-p, 1 a.a a.a 7.11102						

^{*}Percent (%) susceptible data are calculated only when 20 or more isolates of a given species have been tested. Greater statistical validity of %S is seen when 30 or more isolates are included. This Report is a summary of data collected by the Client and provided to the Laboratory and of certain Laboratory test results previously provided to the Client. It is the sole responsibility of the Client to determine that the Report is accurate, to determine what actions, if any, to take as a result of the Report, and to determine that the Report complies with any applicable laws, regulations, or guidelines. LABORATORY EXPRESSLY DISCLAIMS ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, AND LABORATORY EXPRESSLY EXCLUDES ANY LIABILITY FOR ANY LOSS OR DAMAGE, DIRECT OR CONSEQUENTIAL, INCURRED BY CLIENT OR OTHER PERSONS OR ENTITIES RESULTING FROM OR IN ANY WAY RELATED TO THIS REPORT.



CUM 12 MONTH ROLLING ANTIBIOGRAM (UR & NON-UR) / JUN 2021 46867240 KINDRED HOSPITAL SEATTLE-FIRST

	ANTIMICROBIAL			SUSCEPTIBILITI			S - F	ERCE	NT SL	TIBLE	
	STAPA	STAPCN	STEM	STREPN	STRESP						
	MSSA										
# ISOLATES	47	16*	27*	1*	2*						
CEFTAZIDIME			37			_					
CHLORAMPHENICOL			56								
CIPROFLOXACIN	91										
CLINDAMYCIN	83										
ERYTHROMYCIN	64										
GENTAMICIN	98										
LEVOFLOXACIN	91		89								
LINEZOLID	100			:							
MOXIFLOXACIN	91										
DXACILLIN	100										
PENICILLIN	0										
QUINUPRISTIN/DALFOPRISTIN	100										-
RIFAMPIN	100										
TETRACYCLINE	98				-						
TRIMETH-SULFA	100		93	:			'				
VANCOMYCIN	100										

ORGANISM ACRONYM KEY

STAPA MSSA STAPCN Staphylococcus aureus /MSSA Staphylococcus, coagulase neg

STEM STREPN Stenotrophomonas maltophilia

STRESP

Streptococcus pneumoniae Streptococcus viridans

^{*}Percent (%) susceptible data are calculated only when 20 or more isolates of a given species have been tested. Greater statistical validity of %S is seen when 30 or more isolates are included. This Report is a summary of data collected by the Client and provided to the Laboratory and of certain Laboratory test results previously provided to the Client. It is the sole responsibility of the Client to determine that the Report is accurate, to determine what actions, if any, to take as a result of the Report, and to determine that the Report complies with any applicable laws, regulations, or guidelines. LABORATORY EXPRESSLY DISCLAIMS ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, AND LABORATORY EXPRESSLY EXCLUDES ANY LIABILITY FOR ANY LOSS OR DAMAGE, DIRECT OR CONSEQUENTIAL, INCURRED BY CLIENT OR OTHER PERSONS OR ENTITIES RESULTING FROM OR IN ANY WAY RELATED TO THIS REPORT.



CUM 12 MONTH ROLLING ANTIBIOGRAM (UR & NON-UR) / JUN 2021 46866970 KINDRED HOSPITAL SEATTLE-FIRST

	ANTIMICROBIAL		BIAL	SUSC	EPTIE	BLITIE	S - F	PERCENT SUSCE			PTIBLE	
	KLEBSP	MORM	PROTSP	PSEUAE	SERRSP		STAPA MSSA	STEM				
# ISOLATES	1*	1*	2*	7*	1*	1*	1*	1*				
	- :											

ORGANISM ACRONYM KEY

KLEBSP Klebsiella species STAPA MSSA Staphylococcus aureus /MSSA MORM Morganella morganii STEM Stenotrophomonas maltophilia PROTSP Proteus species PSEUAE Pseudomonas aeruginosa

*Percent (%) susceptible data are calculated only when 20 or more isolates of a given species have been tested. Greater statistical validity of %S is seen when 30 or more isolates are included.

SERRSP

STAPA

Serratia species

Staphylococcus aureus

This Report is a summary of data collected by the Client and provided to the Laboratory and of certain Laboratory test results previously provided to the Client. It is the sole responsibility of the Client to determine that the Report is accurate, to determine what actions, if any, to take as a result of the Report, and to determine that the Report complies with any applicable laws, regulations, or guidelines. LABORATORY EXPRESSLY DISCLAIMS ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, AND LABORATORY EXPRESSLY EXCLUDES ANY LIABILITY FOR ANY LOSS OR DAMAGE, DIRECT OR CONSEQUENTIAL, INCURRED BY CLIENT OR OTHER PERSONS OR ENTITIES RESULTING FROM OR IN ANY WAY RELATED TO THIS REPORT.



CUM 12 MONTH ROLLING ANTIBIOGRAM (UR & NON-UR) / JUN 2021 46859825 KINDRED HOSPITAL SEATTLE-FIRST

	ANTIMICROBIAL			SUSCEPTIBILITIES - F				PERCENT SUSCEPTIBLE				
	ENTS	ENTS	PSEUAE									
		ENTFA										
# ISOLATES	1*	1*	1*									
						-						
					:							
												
							<u> </u>					
	12801											
						·						
			·									

ORGANISM ACRONYM KEY

ENTS ENTS ENTFA PSEUAE

Enterococcus species Enterococcus faecalis Pseudomonas aeruginosa

^{*}Percent (%) susceptible data are calculated only when 20 or more isolates of a given species have been tested. Greater statistical validity of %S is seen when 30 or more isolates are included.

This Report is a summary of data collected by the Client and provided to the Laboratory and of certain Laboratory test results previously provided to the Client. It is the sole responsibility of the Client to determine that the Report is accurate, to determine what actions, if any, to take as a result of the Report, and to determine that the Report complies with any applicable laws, regulations, or guidelines. LABORATORY EXPRESSLY DISCLAIMS ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, AND LABORATORY EXPRESSLY EXCLUDES ANY LIABILITY FOR ANY LOSS OR DAMAGE, DIRECT OR CONSEQUENTIAL, INCURRED BY CLIENT OR OTHER PERSONS OR ENTITIES RESULTING FROM OR IN ANY WAY RELATED TO THIS REPORT.



For persons with disabilities, this document is available on request in other formats. To submit a request, please call 1-800-525-0127 (TDD/TTY 1-800-833-6388).